Radu Constantinescu
Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Parkinson Disease | 10 | 2005 | 67 |
Why?
|
Parkinsonian Disorders | 3 | 2007 | 19 |
Why?
|
Levodopa | 5 | 2005 | 28 |
Why?
|
Antiparkinson Agents | 4 | 2005 | 23 |
Why?
|
Neurofilament Proteins | 2 | 2008 | 18 |
Why?
|
Biological Markers | 3 | 2010 | 263 |
Why?
|
Uric Acid | 2 | 2010 | 25 |
Why?
|
Huntington Disease | 2 | 2008 | 30 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2009 | 37 |
Why?
|
Ubiquinone | 1 | 2007 | 11 |
Why?
|
Akathisia, Drug-Induced | 1 | 2007 | 8 |
Why?
|
Benzothiazoles | 1 | 2007 | 22 |
Why?
|
Self-Help Devices | 1 | 2006 | 5 |
Why?
|
Gait | 1 | 2006 | 16 |
Why?
|
Melanoma | 1 | 2007 | 87 |
Why?
|
Nerve Tissue Proteins | 1 | 2008 | 128 |
Why?
|
Skin Neoplasms | 1 | 2007 | 97 |
Why?
|
Middle Aged | 10 | 2005 | 1166 |
Why?
|
Humans | 16 | 2005 | 1858 |
Why?
|
Aged | 9 | 2005 | 992 |
Why?
|
Male | 11 | 2005 | 1558 |
Why?
|
Female | 11 | 2005 | 1646 |
Why?
|
Disease Progression | 2 | 2008 | 244 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 224 |
Why?
|
Case-Control Studies | 2 | 2008 | 284 |
Why?
|
Diagnosis, Differential | 2 | 2008 | 403 |
Why?
|
Double-Blind Method | 2 | 2007 | 274 |
Why?
|
Retrospective Studies | 3 | 2007 | 656 |
Why?
|
Cross-Over Studies | 3 | 2005 | 82 |
Why?
|
Administration, Oral | 3 | 2005 | 170 |
Why?
|
Adult | 6 | 2005 | 1321 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 22 |
Why?
|
Limbic Encephalitis | 1 | 2009 | 1 |
Why?
|
Receptors, GABA-B | 1 | 2009 | 2 |
Why?
|
Neuropsychological Tests | 2 | 2008 | 114 |
Why?
|
Risk | 1 | 2011 | 203 |
Why?
|
Autoimmune Diseases of the Nervous System | 1 | 2009 | 5 |
Why?
|
Proteomics | 1 | 2010 | 36 |
Why?
|
Autoantibodies | 1 | 2009 | 65 |
Why?
|
Apomorphine | 1 | 2008 | 8 |
Why?
|
PubMed | 1 | 2008 | 2 |
Why?
|
Seizures | 1 | 2009 | 79 |
Why?
|
Capsules | 1 | 2007 | 6 |
Why?
|
Gelatin | 1 | 2007 | 11 |
Why?
|
Coenzymes | 1 | 2007 | 16 |
Why?
|
Biological Availability | 1 | 2007 | 36 |
Why?
|
Back Pain | 1 | 2007 | 24 |
Why?
|
Pruritus | 1 | 2007 | 14 |
Why?
|
Trinucleotide Repeat Expansion | 1 | 2008 | 21 |
Why?
|
Sinusitis | 1 | 2007 | 22 |
Why?
|
Area Under Curve | 1 | 2007 | 48 |
Why?
|
Vitamins | 1 | 2007 | 30 |
Why?
|
Headache | 1 | 2007 | 39 |
Why?
|
Incidence | 2 | 2006 | 337 |
Why?
|
Education, Medical, Continuing | 1 | 2007 | 54 |
Why?
|
Severity of Illness Index | 2 | 2005 | 359 |
Why?
|
Population Growth | 1 | 2006 | 7 |
Why?
|
Population Density | 1 | 2006 | 12 |
Why?
|
Internationality | 1 | 2006 | 28 |
Why?
|
Multicenter Studies as Topic | 1 | 2007 | 70 |
Why?
|
Orthotic Devices | 1 | 2006 | 14 |
Why?
|
Probability | 1 | 2007 | 190 |
Why?
|
Forecasting | 1 | 2006 | 148 |
Why?
|
Reference Values | 1 | 2007 | 281 |
Why?
|
Comorbidity | 1 | 2007 | 191 |
Why?
|
Proportional Hazards Models | 1 | 2006 | 123 |
Why?
|
Sex Factors | 1 | 2007 | 286 |
Why?
|
Carbidopa | 1 | 2005 | 10 |
Why?
|
Duodenum | 1 | 2005 | 24 |
Why?
|
Young Adult | 1 | 2008 | 381 |
Why?
|
Cross-Sectional Studies | 1 | 2007 | 254 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2007 | 176 |
Why?
|
Brain | 2 | 2008 | 305 |
Why?
|
Cohort Studies | 1 | 2007 | 333 |
Why?
|
Aged, 80 and over | 2 | 2006 | 602 |
Why?
|
Risk Assessment | 1 | 2006 | 325 |
Why?
|
Time Factors | 1 | 2007 | 896 |
Why?
|
Adolescent | 1 | 2008 | 892 |
Why?
|
Drug Therapy, Combination | 2 | 2005 | 189 |
Why?
|
Quality of Life | 2 | 2005 | 188 |
Why?
|
Methoxyhydroxyphenylglycol | 1 | 2010 | 3 |
Why?
|
Hydroxyindoleacetic Acid | 1 | 2010 | 10 |
Why?
|
Homovanillic Acid | 1 | 2010 | 19 |
Why?
|
alpha-Synuclein | 1 | 2010 | 9 |
Why?
|
Interleukins | 1 | 2010 | 32 |
Why?
|
Amyloid beta-Peptides | 1 | 2010 | 24 |
Why?
|
Paraneoplastic Syndromes, Nervous System | 1 | 2009 | 1 |
Why?
|
Oncogene Proteins | 1 | 2010 | 26 |
Why?
|
Rats, Wistar | 1 | 2009 | 75 |
Why?
|
Antigens, Surface | 1 | 2009 | 51 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2010 | 73 |
Why?
|
Infusions, Subcutaneous | 1 | 2008 | 1 |
Why?
|
tau Proteins | 1 | 2010 | 15 |
Why?
|
Infusion Pumps | 1 | 2008 | 18 |
Why?
|
Dopamine Agents | 1 | 2008 | 19 |
Why?
|
Peptide Fragments | 1 | 2010 | 145 |
Why?
|
Dopamine Agonists | 1 | 2008 | 14 |
Why?
|
Drug Administration Schedule | 1 | 2008 | 193 |
Why?
|
Immunoglobulin G | 1 | 2009 | 192 |
Why?
|
Regression Analysis | 1 | 2008 | 256 |
Why?
|
Lung Neoplasms | 1 | 2009 | 160 |
Why?
|
Suspensions | 1 | 2005 | 8 |
Why?
|
Dyskinesia, Drug-Induced | 1 | 2005 | 11 |
Why?
|
Intubation | 1 | 2005 | 15 |
Why?
|
Videotape Recording | 1 | 2005 | 45 |
Why?
|
Gels | 1 | 2005 | 35 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2008 | 431 |
Why?
|
Cell Line | 1 | 2009 | 375 |
Why?
|
Single-Blind Method | 1 | 2005 | 86 |
Why?
|
Psychomotor Performance | 1 | 2005 | 70 |
Why?
|
Cells, Cultured | 1 | 2009 | 447 |
Why?
|
Neurons | 1 | 2009 | 195 |
Why?
|
Rats | 1 | 2009 | 532 |
Why?
|
Treatment Outcome | 1 | 2008 | 662 |
Why?
|
Questionnaires | 1 | 2005 | 361 |
Why?
|
Risk Factors | 1 | 2006 | 557 |
Why?
|
Animals | 1 | 2009 | 1032 |
Why?
|
